Technologies
PDF


WARF: P07026US

Nanoparticles That Target Dendritic Cells


INVENTORS -

Ferencz Denes, Zsuzsanna Fabry, Matyas Sandor

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing carbon nanoparticles that selectively target dendritic cells and may be used in the development of vaccines.
OVERVIEWDendritic cells play an important role in the process of initiating immune response. They are present in small quantities in tissues, such as skin and lung, that are in contact with the external environment and serve as “border patrols.” Once activated by an antigen, dendritic cells migrate to the lymph tissues where they interact with T and B cells to initiate immune response. As a result, vaccines that stimulate dendritic cells may enhance immunity.
THE INVENTIONUW-Madison researchers have developed a system for delivering vaccines and other biomolecules to dendritic cells. This system includes carbon nanoparticles that are preferentially taken up by dendritic cells, rather than macrophages.

Antigens, dendritic cell-targeting antibodies and dendritic cell-activating substances may be attached to the nanoparticles. The antigens are capable of inducing a specific T-cell response and can be associated with infectious disease or a tumor. When delivered to dendritic cells, these nanoparticles enhance immune response.

Other biomolecules, including targeting compounds, therapeutic agents and detectable labels, can be attached to the nanoparticles as well. Targeting compounds may be attached to enhance the uptake of the nanoparticles by dendritic cells. To treat autoimmune diseases, a cytotoxic agent could be attached to the nanoparticles to selectively target and kill aberrant dendritic cells. Fluorescent or radioactive labels could be added to make it easier to isolate dendritic cells. 
APPLICATIONS
  • Preventing infectious disease
  • Treating cancer
  • Treating autoimmune diseases, such as arthritis, multiple sclerosis and autoimmune diabetes
  • Monitoring, isolating and manipulating dendritic cells
  • Delivering biomolecules to dendritic cells
KEY BENEFITS
  • Capable of initiating a strong immune response
  • Carbon-based magnetic nanoparticles are stable over a large temperature range.
  • Nanoparticles have a large specific surface area that enables the high density attachment of bio-macromolecules, including proteins.
  • Nanoparticles are not toxic or inflammatory.
  • Nanoparticles can be directed to a specific site in a patient using a magnetic field.
  • May enable targeted, localized delivery of antigen
  • A variable magnetic field can be applied to a patient to generate heat in the cells surrounding the nanoparticles.
STAGE OF DEVELOPMENTThe inventors have shown that the nanoparticles are preferentially taken up by dendritic cells and induce a strong immune response in in vitro and in vivo environments. They also have demonstrated that the nanoparticles are non-toxic and do not induce inflammation.
ADDITIONAL INFORMATION
For More Information About the Inventors
Contact Information
For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.